Supplementary Figure S7 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial

Supplementary Figures 7A, 7B and 7C Cetuximab enhances anti-tumor cytokines: Cytokine concentrations in the sample supernatants were determined by enzyme-linked immunosorbent assay (ELISA) using a Luminex assay (R&Dsystems, a bio-techne brand, Minneapolis, MN) according to the manufacturer's protocol. Cetuximab alone decreased pro-tumorigenic IL-6 levels and increased IP-10 suggesting an anti-tumor response (Supplementary Figure 7A and 7B); however, these cytokines were not significantly changed between responders (those with CR, PR, SD) and non-responders. The full panel of tested cytokines, shown in Supplementary Figure 7C.Abbreviations: CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NK: Natural Killer; IL: interleukin; IP: Interferon gamma inducible protein-10 (IP-10).